Stay updated on Dara-Thal-Dex in Relapse Myeloma Clinical Trial

Sign up to get notified when there's something new on the Dara-Thal-Dex in Relapse Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Dara-Thal-Dex in Relapse Myeloma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Additionally, a significant piece of information regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.
    Difference
    0.9%
    Check dated 2025-07-04T03:50:41.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.7%
    Check dated 2025-06-19T19:22:37.000Z thumbnail image
  4. Check
    23 days ago
    No Change Detected
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:07:49.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T05:53:58.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T13:58:18.000Z thumbnail image
  8. Check
    81 days ago
    Change Detected
    Summary
    The webpage has been updated to reflect a new phase 2 study of the combination treatment of Daratumumab, thalidomide, and dexamethasone for relapse or refractory myeloma, including details about the study's collaborators and principal investigator. Additionally, some outdated information regarding previous treatments and survival rates has been removed.
    Difference
    42%
    Check dated 2025-04-16T02:48:20.000Z thumbnail image

Stay in the know with updates to Dara-Thal-Dex in Relapse Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Dara-Thal-Dex in Relapse Myeloma Clinical Trial page.